GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: KPL-716 | KPL716
Compound class:
Antibody
Comment: Vixarelimab (KPL-716) is an anti-oncostatin M (OSM) receptor β subunit monoclonal antibody [1]. It disrupts both interleukin-31 and OSM signalling at the interface between immune cells and connective tissue/stromal cells, by attenuating the MCP-1 response to OSM. The effects of vixarelimab are distinct to those of an anti-IL-31 receptor α monoclonal.
|
Classification ![]() |
|
| Compound class | Antibody |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11350 | vixarelimab |
Synonyms ![]() |
| KPL-716 | KPL716 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 1063 |
| Other databases | |
| GtoPdb PubChem SID | 500839861 |
| Search PubMed clinical trials | vixarelimab |
| Search PubMed titles | vixarelimab |
| Search PubMed titles/abstracts | vixarelimab |